Helicid Neo (Omeprazole)

Helicid Neo (omeprazole) is indicated for the management of acid‑related gastrointestinal disorders.

• Relief of symptoms and mucosal healing in gastroesophageal reflux disease (GERD), including heartburn and acid regurgitation.
• Induction of healing in erosive esophagitis caused by chronic acid exposure.
• Treatment of active duodenal and gastric ulcers, promoting ulcer closure and symptom control.
• Inclusion in multi‑drug regimens for Helicobacter pylori eradication to improve eradication rates.
• Prevention of NSAID‑induced gastric ulcer recurrence in patients requiring long‑term NSAID therapy.

Like other proton‑pump inhibitors, Helicid Neo may be associated with a range of adverse effects, most of which are mild and reversible.

Common

• Headache.
• Diarrhea or loose stools.
• Abdominal pain or dyspepsia.
• Nausea.

Serious

• Severe allergic reactions such as rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile‑associated colitis.
• Low magnesium levels (hypomagnesemia) with prolonged use.

Before starting Helicid Neo, certain precautionary measures should be considered to ensure safe and effective use.

• Assess for known hypersensitivity to omeprazole or other proton‑pump inhibitors.
• Use with caution in patients with severe liver impairment, as drug clearance may be reduced.
• Evaluate the need for long‑term therapy, especially in older adults, because prolonged use can affect nutrient absorption.
• Consider potential risk of bone fractures with extended treatment duration.
• Monitor for signs of infection, such as persistent diarrhea, which may indicate C. difficile overgrowth.
• Discuss pregnancy and breastfeeding status with a healthcare provider, as safety data are limited.

Helicid Neo can interact with several medicines; recognizing these interactions helps avoid reduced efficacy or increased toxicity.

Avoid

• Concomitant use with atazanavir or nelfinavir, where omeprazole markedly reduces antiviral absorption.
• Co‑administration with rilpivirine, which may lower its plasma concentrations.

Use with caution

• Antiplatelet agents such as clopidogrel, where omeprazole may diminish antiplatelet effect.
• Warfarin, as omeprazole can increase INR and bleeding risk.
• Methotrexate, especially high‑dose regimens, due to possible reduced renal clearance.
• Digoxin, where increased serum levels have been reported.